Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
56
12
18
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 56 trials
100.0%
+13.5% vs industry average
25%
14 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (56)
The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
Role: lead
A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
Role: lead
A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
Role: lead
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
Role: lead
Efficacy and Safety Study of 610 in Patients With Severe Asthma
Role: lead
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
Role: lead
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
Role: lead
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
Role: lead
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Role: lead
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
Role: lead
Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
Role: lead
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
Role: lead
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Role: lead
Evaluation of 627 in Healthy Adult Subjects
Role: lead
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
Role: lead
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
Role: lead
601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
Role: lead
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
Role: lead
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
Role: lead
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
Role: lead